Eris Q4 PAT Surges 173% to 279.1 Crores
Eris Lifesciences reported a 173% YoY increase in Q4 net profit to 279.10 Crores, driven by revenue growth of 757 Crores and an EBITDA margin expansion to 36.20%. For the full fiscal year, the company achieved a net profit of 647.51 Crores on revenue of 3,129.42 Crores. The Board declared an interim dividend of Rs 7.21 per share with a record date of May 29, 2026.
*this image is generated using AI for illustrative purposes only.
Eris Lifesciences has reported its audited consolidated financial results for the fourth quarter and fiscal year ended March 31, 2026, posting a sharp jump in net profit to 279.10 Crores compared to 102.35 Crores in the same period last year. Revenue from operations grew to 757 Crores from 705 Crores year-on-year, reflecting broad-based improvement across key financial metrics. For the full fiscal year, the company recorded a net profit of 647.51 Crores on revenue of 3,129.42 Crores.
Q4 Financial Highlights
The company's latest quarterly performance demonstrates a significant improvement in profitability and operational efficiency. The following table summarises the key consolidated financial metrics for the quarter:
| Metric: | Q4 Current | Q4 Previous (YoY) |
|---|---|---|
| Net Profit: | 279.10 Crores | 102.35 Crores |
| Revenue: | 757 Crores | 705 Crores |
| EBITDA: | 274 Crores | 252 Crores |
| EBITDA Margin: | 36.20% | 35.80% |
EBITDA improved to 274 Crores from 252 Crores year-on-year, while EBITDA margin expanded to 36.20% from 35.80%, indicating improved cost efficiency alongside revenue growth.
Segment Performance
The Domestic Branded Formulations (DBF) segment reported a 12% year-on-year revenue growth to Rs. 671 Crores in Q4 FY26, with an EBITDA margin of 37%. The International Business segment recorded a revenue of Rs. 86 Crores for the quarter, impacted by supply chain disruptions, while full-year revenue grew 7% to Rs. 348 Crores.
Sundae Launch and Guidance
The company highlighted a robust start for its Gx Semaglutide brand, Sundae, achieving a 22% market share by prescription volume in April 2026. For FY27, the company provided guidance for DBF revenue growth at 1.3x of CVM growth and an EBITDA margin of 37%.
Dividend Declaration
The Board of Directors has declared an interim dividend of Rs. 7.21 per share (at the rate of 721%) on each fully paid-up equity share of Re. 1/- each for the financial year 2026-27. The record date for determining the eligibility of shareholders for the payment of the interim dividend has been fixed as Friday, May 29, 2026.
Historical Stock Returns for Eris Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.01% | -2.42% | +0.47% | -12.03% | -17.36% | +89.64% |
Can Eris Lifesciences sustain its 36-37% EBITDA margin guidance for FY27 amid potential pricing pressures in the domestic branded formulations market?
How might Sundae's early 22% prescription market share in Semaglutide evolve as more competitors enter the GLP-1 segment in India?
What strategic steps is Eris Lifesciences likely to take to resolve the supply chain disruptions impacting its International Business segment?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
